# TRL for ICMR and DHR funding calls: what health researchers must show

URL: https://zernyxhub.com/blog/trl-for-icmr-dhr-grants
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-11-04
Category: Technology readiness

> ICMR grant TRL requirements: what recent ICMR and DHR calls ask for, from TRL 3 proof of concept to an MD-13 test licence, and the evidence to attach.

**Short answer:** ICMR technology calls increasingly name a readiness stage. The ICMR Intramural MedTech Call 2.0 (January 2026) took only technologies that had completed TRL 3, proof of concept. ICMR's June 2026 Centres for Advanced Research call preferred functional prototypes at TRL 3 or 4. Its 2025 batch manufacturing EoI required an MD-13 test licence.

Health researchers in India usually meet TRL for the first time in a BIRAC form. ICMR calls are now asking for it too, but each call asks differently: one sets a hard minimum, one states a preference, one asks for a regulatory licence instead of a number. If you write the same TRL paragraph for all of them, you will miss what each reviewer is checking.

This post goes through what recent ICMR and Department of Health Research (DHR) calls actually say, and what evidence from the bench answers each. ICMR sits under DHR in the Ministry of Health and Family Welfare, and several DHR schemes are advertised through ICMR's call pages, so researchers often meet both in the same week. The technology calls, where readiness is assessed, mostly come from ICMR's development research side.

## What recent calls ask for

| Call | Released | Readiness asked for | Funding and duration |
|---|---|---|---|
| ICMR Intramural MedTech Call 2.0 | 8 January 2026 | Completed TRL 3 (proof of concept), or at least 10% cost reduction | Ceiling about ₹4 crore per project (higher with DG-ICMR approval), up to 2 years |
| ICMR CAR: priority medical devices and diagnostics | 1 June 2026 | Preference for functional prototypes at TRL 3 or 4 or above | Up to ₹15 crore per centre, up to 5 years |
| ICMR EoI: batch manufacturing for clinical investigation | 1 September 2025 | MD-13 test licence; TRL is a reporting field | 50% at start, 50% on successful test batch reports |
| DHR GIA Scheme for Inter-Sectoral Convergence | Last date 30 September 2025, later extended to 15 November 2025 | No TRL stated | Not stated in the call summary |

Sources: [ICMR Intramural MedTech Call 2.0](https://www.icmr.gov.in/icmrobject/uploads/Call/1767863120_icmr-intramuralmedtechcall2_0-2026.pdf), [ICMR CAR call, June 2026](https://www.icmr.gov.in/icmrobject/uploads/Call/1780307910_car_prioritytechnologydevelopment_01062026.pdf), [ICMR batch manufacturing EoI](https://www.icmr.gov.in/icmrobject/uploads/Call/1756710235_eoi_medtech_icmr_uploaded.pdf), [DHR GIA call](https://www.indiascienceandtechnology.gov.in/announcementsopportunity/dohr-call-research-proposals-under-grant-aid-gia-scheme-inter-sectoral-convergence-coordination).

Two cautions. Eligibility differs sharply: the intramural call was open only to directors of ICMR institutes as principal investigators, and the June 2026 CAR call was restricted to faculty of the top 25 institutions in the NIRF 2025 Overall ranking. And calls are revised. ICMR's call page lists revised CAR calls with a last date of 13 November 2026, so check the current version before you rely on any figure above.

## Reading "completed TRL 3"

The intramural call defines TRL 3 as proof of concept demonstrated. In the lab, that means a specific result, not an idea that ought to work.

For a diagnostic, proof of concept is usually the assay detecting the target in prepared samples with a signal you can distinguish from controls, repeated. For a device, it is a breadboard or first build that performs the core function on the bench. For a drug, it is usually initial in vitro data, with limited in vivo work; [TRL for drug development](https://zernyxhub.com/blog/trl-drug-development) sets out how BIRAC's drug scale treats this and the later stages.

What reviewers look for in the attachment:

1. The experiment, with conditions: sample type, number, controls.
2. The result, with numbers: sensitivity and specificity, signal to noise, output against target.
3. Repeats: how many independent runs, and whether they agreed.
4. Dates and who did the work.

A single good gel image is not completed TRL 3. Three independent runs with controls and a table of results is.

**Where ICMR calls sit on the readiness scale**
- TRL 3: Proof of concept: intramural call minimum
- TRL 4: Functional prototype on the bench
- TRL 5: Test batches under an MD-13 licence
- TRL 6: Pilot clinical investigation
(CAR call preference: TRL 3 to TRL 4)
Device-oriented reading; drug and vaccine scales differ.

## Reading "functional prototypes at TRL 3 or 4"

The June 2026 CAR call used this as a preference in evaluation, not a stated minimum. A functional prototype is something that performs the intended function as an integrated unit, even if it is ugly. For a point-of-care device, the sensor, readout and sample handling work together on the bench. For a diagnostic kit, the reagents are assembled in the intended format and run as a kit, not as separate lab steps.

If you have components working separately but not together, say so, and make integration your first milestone. [Six TRL overstatements](https://zernyxhub.com/blog/trl-overstatement-grant) explains why rating the system at its best component costs more than it gains.

## When the call asks for a licence instead of a TRL

The batch manufacturing EoI is the clearest case. It asked applicants to hold an MD-13 licence for the proposed technology, or to provide it at the time of selection. Under the Medical Devices Rules, 2017, the test licence is applied for on Form MD-12 and issued on Form MD-13, for manufacturing devices for clinical investigation, testing, evaluation, demonstration or training. The EoI excluded therapeutics and vaccine candidates, and released the second half of funding only on submission of a successful analytical testing report of the test batches.

In TRL terms, an MD-13 licence and compliant test batches sit around TRL 5 on device scales. But the call checks the licence, so the licence number is your evidence. [TRL for medical devices](https://zernyxhub.com/blog/trl-medical-devices) maps the regulatory steps to each level.

## What to attach, call by call

| What the call asks | Evidence from the bench | Common gap |
|---|---|---|
| Completed TRL 3 | Proof-of-concept report: conditions, controls, repeats, data table | One run, no controls |
| Functional prototype at TRL 3 or 4 | Photos and test log of the integrated prototype, performance against targets | Components shown separately |
| MD-13 test licence | Licence copy, test batch records, analytical test plan | Licence applied for but not yet issued |
| Commercialisation plan | Intended user, regulatory route, industry partner or transfer plan | Plan written after the science, with no dates |

The intramural call also asked for a commercialisation plan and a short statement on technology readiness for deployment. Treat these as part of the readiness case. A reviewer reading "TRL 3" alongside a plan with named regulatory steps believes the TRL more readily.

**Writing the readiness section of an ICMR proposal**
1. Read the call's wording: Minimum, preference or licence
2. Name your scale: Call's own, BIRAC or NTRAF
3. State current level: Per critical component
4. Attach dated evidence: Conditions, repeats, numbers
5. Show the path: Milestones to the target level

## Which scale to use

ICMR calls reviewed here do not publish a full TRL scale. Where a call names none, use a recognised sector scale and say which. BIRAC publishes sector definitions for drugs, vaccines, and medical devices and diagnostics. The [National Technology Readiness Assessment Framework](https://tdb.gov.in/sites/default/files/2026-01/nationaltechnologyreadinessassessmentframework_final.pdf), from the Office of the Principal Scientific Adviser, includes an annexure for healthcare and pharmaceuticals and pegs a technology one level lower if any critical item or document is missing. That second rule is a good standard to apply to yourself even when the call does not require it.

One honest hedge: these calls change from year to year, and this post is based on the versions linked above. Your call may word readiness differently, and its wording wins.

## A note on IP before you apply

Several of these calls ask for your intellectual property status in a few words. Before you write "patent to be filed", check whether your proof-of-concept data has already been presented at a conference or in a thesis. Disclosure before filing can damage patentability. File first, or describe the work in the proposal without the enabling detail.

If you want a structured check of your level before you write, [TRL Pro](https://app.zernyxhub.com/trl-calculator) assesses technology readiness from TRL 1 to 9 using Zernyx's own copyrighted framework (ZTRAF), which covers more than 60 technology domains and subdomains: you answer questions about your technology and its evidence, and get back an assessed level.

## Common questions

### What TRL does ICMR require for a medtech grant?

It depends on the call. The ICMR Intramural MedTech Call 2.0 (2026) considered only technologies that had completed TRL 3, meaning proof of concept demonstrated, or that would cut cost by at least 10%. Other ICMR calls state a preference or a regulatory milestone instead of a number. Read each call's own text.

### Do DHR grant calls ask for TRL?

Not all of them. The DHR call under the Grant-in-Aid (GIA) Scheme for Inter-Sectoral Convergence and Coordination, with a last date of 30 September 2025 (ICMR later posted an extension to 15 November 2025), described collaborative health research and did not mention technology readiness levels. Technology-specific calls run through ICMR's divisions are where TRL appears.

### What is the MD-13 licence and why does ICMR ask for it?

MD-13 is the test licence under India's Medical Devices Rules, 2017, issued on an application in Form MD-12, to manufacture devices for clinical investigation, testing, evaluation, demonstration or training. ICMR's September 2025 EoI for batch manufacturing for clinical investigation asked applicants to hold an MD-13 licence for the proposed technology, or provide it at the time of selection.

### Which TRL scale should I use in an ICMR proposal?

Use the one the call names. If it names none, say which scale you used, such as BIRAC's sector definitions or the National Technology Readiness Assessment Framework, and support the level with dated evidence.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
